And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured signal to daydream about weekend plans. We have a busy agenda this time around. We plan to hang with some of our short people. We will also provide a rare, guided tour of the Pharmalot ancestral grounds, since only we know where the bodies are buried. Let us know if you would like to join us. Space is limited. And what about you? You could grab your calculator and divine the impact of the looming tax bill or changes that may appear in your cable bill at some point. You could willfully ignore these developments and plan a holiday getaway. Or stand outside and hope to look past the horizon. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Two months after a Gilead Sciences (GILD) drug was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, while others linger on waiting lists, Bloomberg News reports. Five people have received the treatment, called Yescarta, at the 15 cancer hospitals authorized to administer it in the U.S., and waiting lists for the $373,000 treatment have grown to at least 200 people.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy